Teva Pharmaceutical Industries (NYSE:TEVA) Issues FY 2025 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) issued an update on its FY 2025 earnings guidance on Saturday morning. The company provided EPS guidance of 2.450-2.650 for the period, compared to the consensus EPS estimate of 2.560. The company issued revenue guidance of $16.8 billion-$17.2 billion, compared to the consensus revenue estimate of $17.2 billion.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock opened at $16.95 on Friday. The business has a 50 day simple moving average of $15.35 and a two-hundred day simple moving average of $17.41. Teva Pharmaceutical Industries has a 12 month low of $12.47 and a 12 month high of $22.80. The stock has a market capitalization of $19.22 billion, a P/E ratio of -11.69, a PEG ratio of 1.44 and a beta of 0.62. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. The firm had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The business’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.48 earnings per share. As a group, analysts predict that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TEVA has been the subject of several research analyst reports. Bank of America raised their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, May 8th. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and raised their price target for the company from $21.00 to $23.00 in a research note on Monday, May 12th. StockNews.com upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Wednesday, April 23rd. Hsbc Global Res raised Teva Pharmaceutical Industries to a “strong-buy” rating in a report on Monday, April 28th. Finally, Barclays lowered their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Buy” and a consensus price target of $24.43.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Teva Pharmaceutical Industries stock. AQR Capital Management LLC increased its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 24.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,955 shares of the company’s stock after purchasing an additional 4,732 shares during the period. AQR Capital Management LLC’s holdings in Teva Pharmaceutical Industries were worth $368,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.